Miraculins Inc.
TSX VENTURE : MOM

Miraculins Inc.

January 08, 2007 09:01 ET

Miraculins Retains Services of Investor Relations Professional

WINNIPEG, MANITOBA--(CCNMatthews - Jan. 8, 2007) - Miraculins Inc. (TSX VENTURE:MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to introduce Ms. Sandra Benson as Manager, Investor Relations. Ms. Benson will continue to enhance the Company's corporate image and relationship with investors and business partners.

"Our goals are to improve visibility and support throughout the financial community and increase our company's exposure to existing and potential investors." stated Dr. Jim Charlton, President of Miraculins Inc. "We are very pleased to have someone of Ms. Benson's background and professionalism join Miraculins."

Ms. Benson will actively focus on providing a comprehensive investor relations strategy for Miraculins, concentrating on strengthening communications with current and potential shareholders, while increasing market awareness throughout the financial and investment community and the trade media.

Previous to joining the Miraculins team, Ms. Benson gained valuable experience within the financial services industry working for BMO Financial Group and most recently, Investors Group Inc. She holds a Bachelor of Arts in Economics from the University of Manitoba.

"I look forward to communicating the Miraculins story and building shareholder value through increased liquidity and awareness of the Company's stock." said Ms. Benson.

Miraculins has entered into a 12 month renewable agreement with Genesys Venture Inc. (GVI) for the provision of enhanced investor relations services. Ms. Benson is an employee of GVI and will provide services to Miraculins through this agreement.

GVI provides management services to emerging health and biotechnology ventures through an enhanced business incubator model. It employs a team of experienced scientific and business personnel who provide strategic direction to the research, business development and investor relations activities of client companies to ensure their success.

About Miraculins Inc.

Miraculins is discovering, validating and developing biological markers (biomarkers) with clinical relevance for the diagnosis and treatment of cancers with critical unmet needs. The importance of tumor biomarkers for "common" cancers has been widely recognized and acknowledged by cancer experts and leading groups such as the National Cancer Institute and the American Cancer Society. The Company's BEST™ Platform utilizes the concurrent analysis of clinical factors and biological data, and a combination of proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery.

Certain information contained in this press release may be forward-looking statements and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information